Important safety information
Micotil (tilmicosin injection) is approved for the treatment and control of BRD.
IMPORTANT SAFETY INFORMATION
Before using this product, it is important to read the entire product insert, including the boxed human warning. Caution: Federal (USA) law restricts this drug to use by or on the order of a licensed veterinarian. Not for human use. Injection of this drug in humans has been associated with fatalities. Keep out of reach of children. Do not use in automatically powered syringes. Exercise extreme caution to avoid accidental self-injection. In case of human injection, consult a physician immediately and apply ice or cold pack to injection site while avoiding direct contact with the skin. Avoid contact with eyes. Always use proper drug handling procedures to avoid accidental self-injection. Consult your veterinarian on the safe handling and use of all injectable products prior to administration. For use in cattle or sheep only. Inject subcutaneously. Injection of this antibiotic has been shown to be fatal in swine and non-human primates, and may be fatal in horses and goats. Do not use in lambs less than 15 kg body weight. Do not use in female dairy cattle 20 months of age or older. Use in lactating dairy cattle or sheep may cause milk residues. The following adverse reactions have been reported: in cattle: injection site swelling and inflammation, lameness, collapse, anaphylaxis/anaphylactoid reactions, decreased food and water consumption, and death; in sheep: dyspnea and death. Micotil has a pre-slaughter withdrawal time of 42 days.
- CAUTION: Federal law restricts medicated feed containing this veterinary feed directive (VFD) drug to use by or on the order of a licensed veterinarian.
- Cattle intended for human consumption must not be slaughtered within 28 days of the last treatment.
- To assure both food safety and responsible use, treatment must be initiated within the first 45 days of the production period. The treatment should not occur concurrent with or following administration of an injectable macrolide, or within 3 days following administration of a non-macrolide injectable BRD therapy.
- VFD expiration date must not exceed 45 days from the time of issuance. VFDs shall not be refilled.
- Use only in cattle fed in confinement for slaughter.
- Cattle with severe clinical illness should be evaluated for individual treatment with an alternative non-macrolide therapy.
- Do not use in female dairy cattle 20 months of age or older or in veal calves.
- Safety has not been established for cattle intended for breeding.
- Do not allow horses or other equines access to feeds containing tilmicosin.
For Rumensin: Consumption by unapproved species or feeding undiluted may be toxic or fatal. Do not feed to veal calves.
For Tylan Injection: Injection of tylosin in equines has been fatal. Discontinue use in cattle 21 days before slaughter.
For all products: The labels contain complete use information, including cautions and warnings. Always read, understand and follow the labels and use directions.
Rumensin: Cattle fed in confinement for slaughter
For improved feed efficiency: Feed 5 to 40 g/ton of monensin (90% DM basis) continuously in a complete feed to provide 50 to 480 mg/hd/d. No additional improvement in feed efficiency has been shown from feeding monensin at levels greater than 30 g/ton (360 mg/hd/d). Do not self-feed.
For the prevention and control of coccidiosis due to Eimeria bovis and Eimeria zuernii: Feed 10 to 40 g/ton of monensin (90% DM basis) continuously to provide 0.14 to 0.42 mg/lb of body weight/d of monensin, depending upon severity of challenge, up to a maximum of 480 mg/hd/d.
Rumensin: Growing cattle on pasture or in drylot (stockers, feeders, and dairy and beef replacement heifers)
For increased rate of weight gain: Feed 50 to 200 mg/hd/d of monensin in at least 1.0 lb of Type C medicated feed. Or, after the 5th day, feed 400 mg/hd/d every other day in at least 2.0 lbs of Type C medicated feed. The Type C medicated feed must contain 25 to 400 g/ton of monensin (90% DM basis). Do not self feed.
For the prevention and control of coccidiosis due to Eimeria bovis and Eimeria zuernii: Feed at a rate to provide 0.14 to 0.42 mg/lb of body weight/d of monensin up to a maximum of 200 mg/hd/d. The Type C medicated feed must contain 25 to 400 g/ton of monensin (90% DM basis).
Free-choice supplements: Approved supplements must provide not less than 50 nor more than 200 mg/hd/d of monesin.
Rumensin: Mature reproducing beef cows
For improved feed efficiency when receiving supplemental feed: Feed continuously at a rate of 50 to 200 mg/hd/d of monensin. Cows on pasture or in drylot must receive a minimum of 1.0 lb of Type C medicated feed/hd/d. Do not self-feed.
For the prevention and control of coccidiosis due to Eimeria bovis and Eimeria zuernii: Feed at a rate of 0.14 to 0.42 mg/lb of body weight/d of monensin up to a maximum of 200 mg/hd/d.
For the reduction of incidence of liver abscesses associated with Fusobacterium necrophorum and Arcanobacterium pyogenes: Feed continuously as the sole ration at 8 to 10 g/ton of tylosin (90% DM basis) to provide 60 to 90 mg/hd/d.
CAUTION: Federal law restricts medicated feed containing this veterinary feed directive (VFD) drug to use by or on the order of a licensed veterinarian.
Optaflexx: Complete feed
For increased rate of weight gain and improved feed efficiency: Feed 8.2 to 24.6 g/ton of ractopamine hydrochloride (90% DM basis) continuously in a complete feed to provide 70 to 430 mg/hd/d for the last 28 to 42 days on feed.
For increased rate of weight gain, improved feed efficiency and increased carcass leanness: Feed 9.8 to 24.6 g/ton of ractopamine hydrochloride (90% DM basis) continuously in a complete feed to provide 90 to 430 mg/hd/d for the last 28 to 42 days on feed.
Optaflexx: Top dress
For increased rate of weight gain and improved feed efficiency: Feed 70 to 400 mg/hd/d of ractopamine hydrochloride (90% DM basis) continuously in a minimum of 1.0 lb/hd/d top dress Type C medicated feed (maximum 800 g/ton ractopamine hydrochloride) during the last 28 to 42 days on feed
For the control of Bovine Respiratory Disease (BRD) associated with Mannheimia haemolytica, Pasteurella multocida and Histophilus somni in groups of beef and non-lactating dairy cattle, where active BRD has been diagnosed in at least 10% of the animals in the group: Feed continuously for a single, 14-day period at 568 to 757 g/ton of tilmicosin (100% DM basis) in a
Type C medicated feed as the sole ration to provide 12.5 mg/kg of body weight/day.
Administer one dose in the ear subcutaneously according to label directions.
Inject intramuscularly 8 mg/lb one time daily. Treatment should be continued 24 hours following remission of disease signs, not to exceed 5 days. Do not inject more than 10 mL per site.
Vaccine Precautions: Do not use Titanium BRSV 3, Titanium 3 LP, Titanium 3, Titanium IBR LP and Titanium IBR in pregnant cows or in calves nursing pregnant cows. Abortions may result.